MX363853B - Una formulación de aceite marino que comprende resveratrol o sus derivados para su uso en el tratamiento, retraso y/o prevención de la enfermedad de alzheimer. - Google Patents

Una formulación de aceite marino que comprende resveratrol o sus derivados para su uso en el tratamiento, retraso y/o prevención de la enfermedad de alzheimer.

Info

Publication number
MX363853B
MX363853B MX2015016931A MX2015016931A MX363853B MX 363853 B MX363853 B MX 363853B MX 2015016931 A MX2015016931 A MX 2015016931A MX 2015016931 A MX2015016931 A MX 2015016931A MX 363853 B MX363853 B MX 363853B
Authority
MX
Mexico
Prior art keywords
delaying
derivatives
treating
reservatrol
desease
Prior art date
Application number
MX2015016931A
Other languages
English (en)
Other versions
MX2015016931A (es
Inventor
Sande Mathisen Janne
Mathisen Henrik
Original Assignee
Smartfish As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52022528&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX363853(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Smartfish As filed Critical Smartfish As
Publication of MX2015016931A publication Critical patent/MX2015016931A/es
Publication of MX363853B publication Critical patent/MX363853B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/52—Adding ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/60—Fish, e.g. seahorses; Fish eggs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Mycology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Botany (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Microbiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a una formulación que comprende de aceite marino fresco en una emulsión de aceite en agua y resveratrol o sus derivados para su uso en el tratamiento, el retraso y/o la prevención de la enfermedad de Alzheimer o los síntomas asociados con la enfermedad de Alzheimer, incluyendo el deterioro cognitivo leve (MCI).
MX2015016931A 2013-06-13 2014-06-13 Una formulación de aceite marino que comprende resveratrol o sus derivados para su uso en el tratamiento, retraso y/o prevención de la enfermedad de alzheimer. MX363853B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361834455P 2013-06-13 2013-06-13
PCT/NO2014/050099 WO2014200356A1 (en) 2013-06-13 2014-06-13 A marine oil formulation comprising reservatrol or derivatives thereof for use in treating, delaying and/or preventing alzheimer's desease

Publications (2)

Publication Number Publication Date
MX2015016931A MX2015016931A (es) 2016-04-04
MX363853B true MX363853B (es) 2019-04-05

Family

ID=52022528

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015016931A MX363853B (es) 2013-06-13 2014-06-13 Una formulación de aceite marino que comprende resveratrol o sus derivados para su uso en el tratamiento, retraso y/o prevención de la enfermedad de alzheimer.

Country Status (15)

Country Link
US (1) US9717704B2 (es)
EP (1) EP3016666B1 (es)
JP (2) JP6648007B2 (es)
KR (1) KR20160018801A (es)
CN (1) CN105283190A (es)
AU (1) AU2014278839B2 (es)
CA (1) CA2914767A1 (es)
DK (1) DK3016666T3 (es)
ES (1) ES2732307T3 (es)
HK (1) HK1223263A1 (es)
MX (1) MX363853B (es)
PL (1) PL3016666T3 (es)
PT (1) PT3016666T (es)
SI (1) SI3016666T1 (es)
WO (1) WO2014200356A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014254078A1 (en) 2013-04-19 2015-10-15 Bioventures, Llc Combretastatin analogs
EP3004320A4 (en) 2013-06-24 2017-05-17 Wilson Wolf Manufacturing Corporation Closed system device and methods for gas permeable cell culture process
GB201405033D0 (en) 2014-03-20 2014-05-07 Isis Innovation Combination therapy
AU2015240880A1 (en) 2014-03-31 2016-09-15 Bioventures, Llc Disubstituted triazole analogs
NO20160913A1 (en) * 2016-05-27 2017-11-28 Smartfish As Use of a composition comprising marine oil and juice for improving muscle performance.
US20200024249A1 (en) * 2017-02-02 2020-01-23 Bioventures, Llc Methods of protecting against neurodegeneration

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4897388A (en) * 1988-12-20 1990-01-30 Geriatric Research Institute, Inc. Method of treating Alzheimer's disease
US6184248B1 (en) 1996-09-05 2001-02-06 Robert K. K. Lee Compositions and methods for treatment of neurological disorders and neurodegenerative diseases
NO313076B1 (no) * 1999-12-28 2002-08-12 Pronova Biocare As Flytende n¶rings- og/eller nytelsesmiddel og fremgangsmåte for fremstilling derav
US6964969B2 (en) * 2001-04-19 2005-11-15 Mccleary Edward Larry Composition and method for treating impaired or deteriorating neurological function
US7582674B2 (en) 2003-05-27 2009-09-01 Dsm Ip Assets B.V. Nutraceutical compositions and use thereof
NO322041B1 (no) 2004-10-22 2006-08-07 Pharmalogica As Naeringsmiddelsupplement inneholdende fiskeolje og melkefaststoff som emulgator og fremgangsmate for fremstilling.
US20060172012A1 (en) * 2005-01-28 2006-08-03 Finley John W Anti-inflammatory supplement compositions and regimens to reduce cardiovascular disease risks
NO323665B1 (no) 2005-06-27 2007-06-18 Pharmalogica As Drikk omfattende fiskeolje og probiotiske bakterier og fremgangsmate for fremstilling.
NO324262B1 (no) 2005-11-29 2007-09-17 Pharmalogica As Bruksklar sammensetning omfattende fiskeolje og juice og fremstilling av denne, samt en forseglet beholder.
US20080058418A1 (en) * 2006-09-06 2008-03-06 The Coca-Cola Company Stable polyunsaturated fatty acid emulsions and methods for inhibiting, suppressing, or reducing degradation of polyunsaturated fatty acids in an emulsion
DE202007013532U1 (de) * 2007-09-26 2007-12-13 Orthomol Pharmazeutische Vertriebs Gmbh Zusammensetzung enthaltende Phospholipide, geeignet zur Stärkung der Gehirn- und Gedächtnisfunktion
NO20081487L (no) * 2008-03-27 2009-09-28 Smartfish As Helsefremmende drikk
NO333013B1 (no) * 2009-07-06 2013-02-18 Smartfish As Sammensetning omfattende bioaktive aminosyrer eller derivater derav og marin olje i en stabil olje-i-vannemulsjon, og fremgangsmate for fremstilling av nevnte sammensetning.
EP2279667A1 (en) * 2009-07-30 2011-02-02 Brudy Technology, S.L. Vegetable and marine oil or fat compositions enriched with DHA or EPA and C18 or higher fatty acid
WO2012025229A1 (en) * 2010-08-27 2012-03-01 Persavita Ltd. Composition and method of manufacture
MX359453B (es) * 2011-03-18 2018-09-28 Nestec Sa Composiciones y métodos útiles para aliviar los padecimientos relacionados con la edad.
WO2014000264A1 (en) 2012-06-29 2014-01-03 Qualcomm Incorporated Td-scdma rscp measurement correlation

Also Published As

Publication number Publication date
PT3016666T (pt) 2019-07-11
MX2015016931A (es) 2016-04-04
PL3016666T3 (pl) 2019-09-30
AU2014278839B2 (en) 2019-06-20
JP2016523857A (ja) 2016-08-12
EP3016666A4 (en) 2017-03-15
DK3016666T3 (da) 2019-07-01
WO2014200356A1 (en) 2014-12-18
CA2914767A1 (en) 2014-12-18
SI3016666T1 (sl) 2019-09-30
EP3016666B1 (en) 2019-05-15
JP6648007B2 (ja) 2020-02-14
US20150031653A1 (en) 2015-01-29
ES2732307T3 (es) 2019-11-21
AU2014278839A1 (en) 2015-12-10
EP3016666A1 (en) 2016-05-11
US9717704B2 (en) 2017-08-01
JP2019081807A (ja) 2019-05-30
HK1223263A1 (zh) 2017-07-28
CN105283190A (zh) 2016-01-27
KR20160018801A (ko) 2016-02-17

Similar Documents

Publication Publication Date Title
PH12015502310B1 (en) Pharmaceutical composition, methods for treating and uses thereof
MX2015016931A (es) Una formulacion de aceite marino que comprende reservatrol o sus derivados para su uso en el tratamiento, retraso y/o prevencion de la enfermedad de alzheimer.
CL2015000331A1 (es) Compuestos derivados de piridazina 1,4-disustitutidos; composicion y combinacion farmaceutica que los comprende y uso en el tratamiento de la atrofia muscular espinal.
CL2017002781A1 (es) Métodos de tratamiento de enfermedad de alzheimer
BR112016029226A2 (pt) métodos e composições para o tratamento de úlceras
MX2016000364A (es) Metodos para tratar o prevenir afecciones oftalmologicas.
BR112015020466A2 (pt) inibidores de cdc7
CL2015003343A1 (es) Composición farmacéutica que comprende un agente terapéutico modificado en base a hemoglobina, para el tratamiento para tratar el cáncer, e imágenes de diagnóstico.
PH12019501018A1 (en) Pharmaceutical composition, methods for treating and uses thereof
MX370055B (es) Uso de una composición que comprende aceite de pescado y jugo para el tratamiento y/o postratamiento de cáncer.
MY172040A (en) Synergistic dietary supplement for enhancing physical performance
WO2015031598A3 (en) Therapeutic dnp derivatives and methods using same
BR112015010039A2 (pt) tratamento de câncer com pomalidomida em um individuo com disfunção renal
BR112015022513A2 (pt) produto e método para tratamento de diarreia
AR100028A1 (es) Composiciones nutricionales que contienen ácido estearidónico
BR112015024703A2 (pt) formulação farmacêutica, método de tratamento e/ou prevenção de restenose e kit para o tratamento e/ou prevenção de restenose
MX2017010526A (es) Mezclas de aceite, procesos para la preparacion de estas y su uso en formulas.
BR112015024877A2 (pt) vacinas que compreendem polipeptídeos de leishmania para o tratamento e diagnóstico de leishmaniose
MX2015013739A (es) Potenciadores de solubilidad del agua a base de glucogeno.
BR112018071123A2 (pt) (+)-azasetron para uso no tratamento de distúrbios de ouvido
NO20160913A1 (en) Use of a composition comprising marine oil and juice for improving muscle performance.
BR112016028402A2 (pt) toxina botulínica para uso no tratamento da paratonia
MX365920B (es) Uso de un extracto vegetal para la pérdida de pelo.
BR112018012295A2 (pt) glicoproteína v solúvel para tratar doenças trombóticas
Wi Establishment of Emergency Operating System at On-Scene and Development of Cooperation Training Program for Response Activities among Agencies

Legal Events

Date Code Title Description
FG Grant or registration